PERSONALIZED MEDICINE AS AN UPDATED MODEL OF NATIONAL HEALTH-CARE SYSTEM.PART 1. STRATEGIC ASPECTS OF INFRASTRUCTURE

The article considers the key problems of the transition of the national health-care system to a new platform of personalized medicine and, in particular, pediatrics. The first part, published in this issue, analyzes the most important of the necessary aspects of the infrastructure of the new model. Evidence is given of the extreme urgency of introducing a new model of predictive, preventive and personalized medicine (PPPM). The result of implementation should be breakthrough success in solving many epidemiological, diagnostic, curative, preventive, social and economic problems. It is emphasized that neonatology and pediatrics are the most important link in this paradigm. When considering the potential architectonics of the model, important characteristics of its main segments are revealed. Diagnostic principles (genotyping, targeting, and dynamic screening of biomarkers) and arsenal (genomics, proteomics, metabolomics, mathematical modeling tools, etc.) of personalized medicine are presented. Attention is focused on the need to create information (global, regional and target-specific) banks that are necessary for monitoring individual health. The need to create a new social decision-making mechanism for selecting a preventive protocol that minimizes the risks of the disease or prevents its development is discussed. Four categories of basic programs of medical and social support of persons from the risk category are considered. The necessary conditions for translating these programs into practice are presented. The main tasks and problems of developing the principles for the preparation of preventive-prophylactic and protocols of medical rehabilitation for personalized medicine were discussed. 

1. Oh S.M., Stefani K.M., Kim H.C. Development and Application of Chronic Disease Risk Prediction Models. Yonsei Med J 2014; 55(4): 853–860. DOI: 10.3349/ymj.2014.55.4.853.

2. Kewal K. J. Textbook of Personalized Medicine. Springer, 2009; 365.

3. Сучков С.В., Rose N., Notkins A., Golubnichaia O., von Herrath M., Legg M., Marshall T. Введение в предиктивно-превентивную медицину: опыт прошлого и реальности дня завтрашнего, Тер архив 2012; 84(8), 81–85. [Suchkov S.V., Rose N., Notkins A., Golubnichaia O., Herrath M.von, Legg M., Marshall T. Introduction to preventive and predictive medicine: past experience and future reality. Ter arkhiv 2012; 84(8), 81–85. (in Russ)]

4. Гнатенко Д.А., Костюшев Д.С., Андреева А.В., Филатова Г.А., Notkins A., von Herrath M., Сучков С.В. Молекулярные и клеточные мишени как основа доклинической диагностики сахарного диабета типа 1: проблемы и перспективы, Молекулярная медицина 2012; 6: 22–31. [Gnatenko D.A., Kostjushev D.S., Andreeva A.V., Filatova G.A., Notkins A., von Herrath M., Suchkov S.V. Molecular and cellular targets as the basis of preclinical diagnosis of type 1 diabetes: problems and prospects. Molecular medicine 2012; 6: 22–31. (in Russ)]

5. Галимзянов Х.М., Тризно Н.Н., Лопухин Ю.М., Бодрова Т.А., Ноткинс A.Л., Сучкова Е.Н. и др. Предиктивно-превентивная и персонифицированная медицина как новая отрасль здравоохранения и ее перспективы, Астраханский медицинский журнал 2013; 8(1): 64–70. [Galimzjanov H.M., Trizno N.N., Lopuhin Yu.M., Bodrova T.A., Notkins A.L., Suchkova E.N. et al. The predictive-preventive and personalied medicine as a new branch of health protection and its perspectives. Astrahanskij meditsinskij zhurnal 2013; 8(1): 64–70. (in Russ)]

6. Сучков С.В., Мартынов Л.А., Винокуров И.А., Костюшев Д.С., Андреева А.А., Гаджиева С.И. и др. Перспективы развития доклинической диагностики в рамках задач превентивно-профилактической и предиктивной медицины, Эфферентная и физико-химическая медицина 2011; 3: 45–56. [Suchkov S.V., Martynov L.A., Vinokurov I.A., Kostjushev D.S., Andreeva A.A., Gadzhieva S.I., et al. Prospects for the development of preclinical diagnostics in the framework of preventive-preventive and predictive medicine, Efferentnaja i fiziko-himicheskaja meditsina 2011; 3: 45–56. (in Russ)]

7. Сучков С.В., Гнатенко Д.А., Костюшев Д.С., Крынский С.А., Пальцев М.А. Протеомика как фундаментальный инструмент доклинического скрининга, верификации анализов и оценки применяемой терапии. Вестник РАМН 2013; 1: 65–71. [Suchkov S.V., Gnatenko D.A., Kostushev D.S., Krynskiy S.A., Paltsev M.A. Proteomics as a fundamental tool for subclinical screening, tests verification and assessment of applied therapy. Annals of the Russian academy of medical sciences 2013; 1: 65–71. (in Russ)]

8. Cornetta K., Brown C.G. Perspective: Balancing Personalized Medicine and Personalized Care. Acad Med 2013; 88(3): 309–313.

9. Uhlen M., Fagerberg L., Hallstrom B.M., Lindskog C., Oksvold P., Mardinoglu A., et al. Tissue-based map of the human proteome. Science 2015; 347(6220): 1260419.

10. Vegter S., Boersma C., Rozenbaum M., Wilffert B., Navis G., Postma M.J. Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines. Pharmacoeconomics 2008; 26: 569–587.

11. Van Bebber S.L., Trosman J.R., Liang S.Y., Wang G., Marshall D.A., Knight S., Phillips K.A. Capacity building for assessing new technologies: approaches to examining personalized medicine in practice. Per Med 2010; 7(4): 427–439. DOI:10.2217/pme.10.36

12. Kostyushev D., Tsarev I., Gnatenko D., Paltsev M., Suchkov S. Myelin-associated serological targets as applicable to diagnostic tools to be used at the preclinical and transient stages of multiple sclerosis progression, Open J Immunology 2011; 1(3): 80–86.

13. Ивкин Д.Ю., Лисицкий Д.С., Чистякова Е.Ю., Галагудза М.М., Захаров Е. А., Карпов А.А. и др. МикроРНК как предиктивный диагностический инструмент и многообещающая мишень для лекарственных средств в лечении хронических сердечных расстройств для использования у пациентов и лиц из группы риска, Российские биомедицинские исследования 2016; 1(1): 4–17. [Ivkin D.Yu., Lisickij D.S., Chistjakova E.Yu., Galagudza M.M., Zaharov E.A., Karpov A.A. et al. MicroRNA as a predictive diagnostic tool and a promising target for drugs in the treatment of chronic cardiac disorders for use in patients and individuals at risk. Russian biomedical research 2016; 1(1): 4–17. (in Russ)]

14. Horgan D., Jansen M., Leyens L., Lal J.A., Sudbrak R., Hackenitz E. et al. An Index of Barriers for the Implementation of Personalised Medicine and Pharmacogenomics in Europe. Public Health Genomics 2014; 17: 287–298.

15. Berkenstadt M., Shiloh S., Barkai G., Katznelson M.B-M., Goldman B. Perceived personal control ( PPC): a new concept in measuring outcome of genetic counselling. Am J Med Genet 1999; 82: 53–59.

16. Табаксоева Ж.А., Агиров М.М., Черепахина Н.Е., Шогенов З.С., Чемберлен В., Сучков С.В., Потешкина Н.Г. Микробный пейзаж и его место в развитии хронически рецидивирующих инфекционных заболеваний. Рус мед журн 2011; 6: 53–60. [Tabaksoeva Zh.A., Agirov M.M., Cherepahina N.E., Shogenov Z.S., Chamberlin W., Suchkov S.V., Poteshkina N.G. Microbial landscape and its place in the development of chronic relapsing infectious diseases. Rus Med J 2011; 6: 53–60. (in Russ)]

17. Каминский И.П., Огородова Л.М., Патрушев М.В., Чулок А.А. Медицина будущего: возможности для прорыва сквозь призму технологического прогноза. Форсайт 2013; 7(1): 14–27. [Kaminskij I.P., Ogorodova L.M., Patrushev M.V, Chulok A.A. Medicine of the future: opportunities for breakthrough through the prism of technological prognosis. Foresight-Russia 2013; 7(1): 14–27 (in Russ)]

18. Scott S.A. Personalizing Medicine with Clinical Pharmacogenetics. Genetics in Medicine 2011; 13: 987–995.

19. Mowat C., Cole A., Windsor A., Ahmad T., Arnott I., Driscoll R. et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60: 571–607. DOI: 10.1136/ gut.2010.224154.

20. Costigliola V. ( ed.) Healthcare Overview: New perspectives, Advances in Predictive, Preventive and Personalised Medicine, Springer Science+Business Media Dordrecht, 2012; 415-421.

21. Department of Health. 2010. Specialised Services National Definition Set: 20 Medical genetic services (all ages). 2010.

22. Rogowski W. Current impact of gene technology on healthcare. A map of economic assessments. Health Policy 2007; 80(2): 340–357.

23. Gabibov A.G., Paltsev M.A., Suchkov S.V. Antibody-Associated Proteolysis in Surveillance of Autoimmune Demyelination: Clinical and Preclinical Issues. Future Neurology 2011; 6: 303–305.

24. Саутин М.E., Черепахин Д.С., Земсков В.М., Олейников В.А., Старков Ю.Г., Сучков С.В. Современные технологии и протоколы молекулярной визуализации (molecular imaging) в практике эндохирургии (точка зрения). Рус мед журн Хирургия 2013; 15: 793–796. [Sautin M.E., Cherepahin D.S., Zemskov V.M., Olejnikov V.A., Starkov Yu.G., Suchkov S.V. Modern technologies and protocols molecular imaging in the practice of endosurgery (point of view). Rus Med J 2013; 15: 793–796. (in Russ)]

25. Букина Ю.Д., Швед П.Г., Мандрик М.А., Сучков С.В. Cовременная стратегия ПППМ при лечении хронических и хронически-рецидивирующих заболеваний. Международный научный институт «Educatio» IV (11), 2015; 18–20. [Bukina Yu.D., Shved P.G., Mandrik M.A., Suchkov S.V. Modern strategy PPPM in the treatment of chronic and chronic-relapsing diseases, International Research Institute « Educatio» IV (11), 2015; 18–20. (in Russ)]

26. Бодрова Т.А., Костюшев Д.С., Антонова Е.Н., Гнатенко Д.А., Бочарова М.О., Лопухин Ю.М., Пальцев М.А., Сучков С.В. Введение в предиктивно-превентивную медицину: опыт прошлого и реалии дня завтрашнего. Вестник РАМН 2013; 1: 58–64. [Bodrova T.А., Kostushev D.S., Antonova E.Н, Gnatento D.A., Bocharova M.O, Lopukhin Yu.M., Paltsev M.A., Suchkov S.V. Introduction into PPPM: experience of the past and tomorrow’s reality. Vestn Rossiiskoi akademii meditsinskikh nauk ( Annals of the Russian academy of medical sciences) 2013; 1: 58–64. (in Russ)]

27. Munshi M.N., Florez H., Huang E.S., Kalyani R.R., Mupanomunda M., Pandya N. et al. Management of Diabetes in Long-term Care and Skilled Nursing Facilities: A Position Statement of the American Diabetes Association. Diabetes Care 2016; 39(2): 308–318.

28. Milewicz D.M, Regalado E.S. Use of genetics for personalized management of heritable thoracic aortic disease: how do we get there? J Thorac Cardiovasc Surg 2015; 149(2 Suppl): S3–5.

29. Agboola S.O., Ball M., Kvedar J.C., Jethwani K. The future of Connected Health in preventive medicine. QJM 2013; 106(9): 791–794.

30. Bodrova T.A., Kostyushev D.S., Antonova E.N. Introduction into PPPM as a New Paradigm of Public Health Service: An Integrative View. EPMA J 2012; 3: 16.